GlassScriptPhysician profile
David J Cancian
NPI 1962496539
$5,686.66
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,050 · 2020: $406 · 2021: $485 · 2022: $1,078 · 2023: $1,261 · 2024: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621 · Education: $46.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.07 |
| Education | $46.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $982.54 | 2019-2024 | Breztri, Farxiga |
| Novo Nordisk INC | $617.50 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $426.58 | 2019-2023 | Xarelto |
| Pfizer INC. | $402.85 | 2019-2021 | |
| Abbvie INC. | $386.24 | 2021-2023 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $357.33 | 2019-2024 | Mounjaro |
| Amgen INC. | $305.60 | 2019-2024 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.85 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $263.94 | 2019-2024 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $248.04 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $241.28 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Idorsia Pharmaceuticals US INC | $172.63 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $140.25 | 2022-2023 | Myrbetriq, Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.91 | 2019-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $103.25 | 2019-2023 | Eliquis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $89.57 | 2019 | |
| Tolmar, INC. | $81.68 | 2023 | |
| Amarin Pharma, INC. | $72.59 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $68.46 | 2019 | |
| Exact Sciences Corporation | $68.08 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $47.63 | 2021-2022 | |
| Abbott Laboratories | $43.03 | 2021-2022 | |
| Sanofi Pasteur INC. | $40.63 | 2019-2022 | |
| Dynavax Technologies Corporation | $37.01 | 2022-2023 | Heplisav-B |
| Almatica Pharma LLC | $31.06 | 2022 | |
| Acerus Pharmaceuticals Corporation | $24.86 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cancian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.